WO2013134376A1 - Modulateurs allostériques positifs pour récepteurs de mélanocortine - Google Patents

Modulateurs allostériques positifs pour récepteurs de mélanocortine Download PDF

Info

Publication number
WO2013134376A1
WO2013134376A1 PCT/US2013/029353 US2013029353W WO2013134376A1 WO 2013134376 A1 WO2013134376 A1 WO 2013134376A1 US 2013029353 W US2013029353 W US 2013029353W WO 2013134376 A1 WO2013134376 A1 WO 2013134376A1
Authority
WO
WIPO (PCT)
Prior art keywords
melanocortin
obesity
receptor
melanocortin receptor
positive allosteric
Prior art date
Application number
PCT/US2013/029353
Other languages
English (en)
Inventor
Roger D. Cone
Julien A. SEBAG
Jacques PANTEL
Savannah Y. WILLIAMS
C. David Weaver
Gary A. SULIKOWSKI
Craig W. Lindsley
Padma S. PORTONOVA
Chao Zhang
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Priority to US14/383,715 priority Critical patent/US9744171B2/en
Publication of WO2013134376A1 publication Critical patent/WO2013134376A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D231/08—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen or sulfur atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/18—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Definitions

  • the present disclosure generally relates to compositions and methods for treating obesity and obesity-related disorders, and more particularly to the use of positive allosteric modulators of melanocortin receptors.
  • the adipostat is the mechanism by which the brain detects and maintains constant levels of energy stored in adipocytes in the form of lipids.
  • Key elements of the adipostat include the adipocyte-derived hormone leptin that is expressed in proportion to energy levels and serves to communicate this information to the central nervous system and the central circuits, which sense and respond to leptin. Blockade of one of these circuits, the central melanocortin system, disrupts leptin action, as well as a variety of acute physiological systems involved in energy intake and expenditure, and causes a distinct obesity syndrome in mice and humans, characterized by increased adiposity as well as increased linear growth.
  • the melanocortin circuitry of the central nervous system is a critical component of the adipostat. Srisai et al, Endocrinology, 152(3): 890-902 (2011). Activation of these circuits inhibits food intake and stimulates energy expenditure.
  • the melanocortin-4 receptor (MC4R) is a major component of the machinery controlling food intake and energy expenditure. Consequently, MC4R haploinsufficiency due to mutations in the receptor is responsible for up to 5% of early onset obesity. For this reason, MC4R has been a target of the major pharmaceutical companies for the development of drugs for the treatment of common obesity. The first clinical trials of potent MC4R agonists, however, failed due to pressor activity.
  • the MC4R a G-protein coupled receptor (GPCR)
  • GPCR G-protein coupled receptor
  • cAMP production and ERK1/2 mitogen-activated protein kinase phosphorylation.
  • Potent orthosteric agonists can activate GPCR signaling in magnitude and in temporo-spatial patterns that exceed those exhibited under normal physiological patterns of activation. Such orthosteric agonists may thus tend to induce side effects.
  • allosteric modulators have provided a successful alternative to conventional orthosteric agents, albeit for indications other than obesity.
  • the positive allosteric modulator is an in vivo activator of the MC4R, while in other embodiments the positive allosteric modulator is a ⁇ -arresting blocker.
  • the method includes contacting a melanocortin receptor with a positive allosteric modulator compound, while in another embodiment the method includes contacting a melanocortin receptor with a positive allosteric modulator compound to block coupling of a melanocortin receptor to ⁇ -arrestin.
  • a method for treating obesity or an obesity-related disorder in a subject includes administering a therapeutically effective amount of a pharmaceutical composition including a positive allosteric modulator for a melanocortin receptor together with a pharmaceutically acceptable carrier.
  • the obesity or obesity-related disorder is mediated by dysfunctional melanocortin receptor signaling, while in further embodiments the disorder is mediated by dysfunctional melanocortin-4 receptor (MC4R) signaling.
  • M4R dysfunctional melanocortin-4 receptor
  • Figure 1 provides a schematic flow chart showing the 165 positive allosteric modulators of the MC4R, and the pharmacological and in vivo characterization of subsets thereof.
  • Figure 2 provides graphic examples of the pharmacological analyses used to identify small molecule positive allosteric modulators of the MC4R. Curves show real-time measurement of cAMP production in the MC4R-GLO cell line, as reported by luciferase luminescence, following successive treatments with small molecule compounds (first arrow), or doses indicated of a-MSH or isoproterenol (second arrow). Luminescence recording was performed in 384 well plates using a Hammamatsu FDSS6000 plate reader at 37°C for 26 min. Luminescence is reported as the average of quadruplicates ⁇ SEM for a representative experiment.
  • Figure 3 provides a pharmacological characterization of MC4R PAMS.
  • A Example of the ability of a typical MC4R PAM (compound C, 10uM) to increase the responsiveness of the hMC4R to graded doses (indicated) of a-MSH.
  • B Concentration response curves for compound A on MC4R expressing cells in the presence of a submaximal concentration of the melanocortin agonist a-MSH.
  • C Traces of cAMP response in MC3R and MC4R expressing cells in the presence of increasing concentrations of three representative compounds displaying different degrees of specificity for allosteric modulation of two closely related melanocortin receptors.
  • Figure 4 provides a schematic representation of the HTS assay used to identify MC4R PAMS using a pGLO reporter to record ability of library compounds to enhance the cellular response to an EC20 dose of a-MSH.
  • Figure 5 provides graphs shown the activity of indicated MC4R PAM compounds and control agonists at the MC4R in vivo using a zebrafish growth assay.
  • the MC4R regulates both adiposity and somatic growth in all vertebrates tested.
  • the MC4R regulates the linear growth of zebrafish larvae from 0-5 days post-fertilization, with activation of the receptor inhibiting growth.
  • the ability of the MC4R PAM compounds indicated to activate the MC4R and inhibit growth is tested by treating wild type zebrafish and MC4R -/- zebrafish with drug.
  • 45 live embryos were transferred into single wells of a 12- well cell culture plate in 4ml fresh egg water. 10 mM stock compound solutions were prepared in 100% DMSO. A 4 ⁇ L compound solution or 40 ⁇ L peptide solution was added and mixed into each well to make 10 ⁇ L final concentration with 0.1% DMSO. Wells with 0.1% DMSO or 10 ⁇ ⁇ -MSH were included as vehicle or positive controls, respectively. Compound/peptide solutions were changed daily. Embryos were raised under standard light/dark cycle at 28 °C.
  • a-MSH the endogenous agonist of the MC4R
  • NDP-MSH a potent synthetic peptide agonist of the MC4R
  • THIQ a small molecule orthosteric agonist of the MC4R.
  • Figure 6 provides a bar graph showing a reduction in high fat diet-induced weight gain in mice by treatment with VU0055768.
  • organic group is used to mean a hydrocarbon group that is classified as an aliphatic group, cyclic group, or combination of aliphatic and cyclic groups (e.g., alkaryl and aralkyl groups).
  • suitable organic groups for compounds are those that do not interfere with the positive allosteric modulation activity.
  • aliphatic group means a saturated or unsaturated linear or branched hydrocarbon group. This term is used to encompass alkyl, alkenyl, and alkynyl groups, for example.
  • alkyl As used herein, the terms "alkyl”, “alkenyl”, and the prefix “alk-” are inclusive of straight chain groups and branched chain groups. Unless otherwise specified, these groups contain from 1 to 20 carbon atoms, with alkenyl groups containing from 2 to 20 carbon atoms. In some embodiments, these groups have a total of at most 10 carbon atoms, at most 8 carbon atoms, at most 6 carbon atoms, or at most 4 carbon atoms. Alkyl groups including 4 or fewer carbon atoms can also be referred to as lower alkyl groups.
  • Alkyl groups can also be referred to by the number of carbon atoms that they include (i.e., C1 - C4 alkyl groups are alky groups including 1-4 carbon atoms). Particular alkyl groups can be abbreviated by well-known abbreviates; e.g., Me for methyl and Et for ethyl.
  • Cycloalkyl refers to an alkyl group (i.e., an alkyl, alkenyl, or alkynyl group) that forms a ring structure.
  • Cyclic groups can be monocyclic or polycyclic and preferably have from 3 to 10 ring carbon atoms.
  • a cycloalkyl group can be attached to the main structure via an alkyl group including 4 or less carbon atoms.
  • Exemplary cyclic groups include cyclopropyl, cyclopropylmethyl, cyclopentyl, cyclohexyl, adamantyl, and substituted and unsubstituted bornyl, norbornyl, and norbornenyl.
  • alkylene and alkenylene are the divalent forms of the “alkyl” and “alkenyl” groups defined above.
  • alkylenyl and alkenylenyl are used when “alkylene” and “alkenylene", respectively, are substituted.
  • an arylalkylenyl group comprises an alkylene moiety to which an aryl group is attached.
  • haloalkyl is inclusive of groups that are substituted by one or more halogen atoms, including perfluorinated groups. This is also true of other groups that include the prefix "halo-”. Examples of suitable haloalkyl groups are chloromethyl, trifluoromethyl, and the like. Halo moieties include chlorine, bromine, fluorine, and iodine.
  • aryl as used herein includes carbocyclic aromatic rings or ring systems. Examples of aryl groups include phenyl, naphthyl, biphenyl, fluorenyl and indenyl. Aryl groups maybe substituted or unsubstituted.
  • heteroatom refers to the atoms O, S, or N.
  • heteroaryl includes aromatic rings or ring systems that contain at least one ring heteroatom (eg., O, S, N).
  • heteroaryl includes a ring or ring system that contains 2 to 12 carbon atoms, 1 to 3 rings, 1 to 4 heteroatoms, and O, S, and/or N as the heteroatoms.
  • Suitable heteroaryl groups include furyl, thienyl, pyridyl, quinolinyl, isoquinolinyl, indolyl, isoindolyl, triazolyl, pyrrolyl, tetrazolyl, imidazolyl, pyrazolyi, oxazolyl, thiazolyl, benzofuranyl, benzothiophenyl, carbazolyl, benzoxazolyl, pyrimidinyl, benzimidazolyl, quinoxalinyl, benzothiazolyl, naphthyridinyl, isoxazolyl, isothiazolyl, purinyl, quinazolinyl, pyrazinyl, 1-oxidopyridyl, pyridazinyl, triazinyl, tetrazinyl, oxadiazolyl, thiadiazolyl, and so on.
  • arylene and heteroarylene are the divalent forms of the "aryl” and “heteroaryl” groups defined above.
  • arylenyl and heteroarylenyl are used when “arylene” and “heteroarylene", respectively, are substituted.
  • an alkylarylenyl group comprises an arylene moiety to which an alkyl group is attached.
  • each group (or substituent) is independently selected, whether explicitly stated or not.
  • each R group is independently selected for the formula -C(O)-NR2
  • group and “moiety” are used to differentiate between chemical species that allow for substitution or that may be substituted and those that do not so allow for substitution or may not be so substituted.
  • group when the term “group” is used to describe a chemical substituent, the described chemical material includes the unsubstituted group and that group with nonperoxidic O, N, S, Si, or F atoms, for example, in the chain as well as carbonyl groups or other conventional substituents.
  • moiety is used to describe a chemical compound or substituent, only an unsubstituted chemical material is intended to be included.
  • alkyl group is intended to include not only pure open chain saturated hydrocarbon alkyl substituents, such as methyl, ethyl, propyl, tert- butyl, and the like, but also alkyl substituents bearing further substituents known in the art, such as hydroxy, alkoxy, alkylsulfonyl, halogen atoms, cyano, nitro, amino, carboxyl, etc.
  • alkyl group includes ether groups, haloalkyls, nitroalkyls, carboxyalkyls, hydroxyalkyls, cyanoalkyls, etc.
  • the phrase “alkyl moiety” is limited to the inclusion of only pure open chain saturated hydrocarbon alkyl substituents, such as methyl, ethyl, propyl, tert-butyl, and the like.
  • the invention is inclusive of the compounds described herein in any of their pharmaceutically acceptable forms, including isomers (e.g., diastereomers and enantiomers), tautomers, salts, solvates, polymorphs, prodrugs, and the like.
  • the invention specifically includes each of the compound's enantiomers as well as racemic mixtures of the enantiomers. This is true regardless of whether or not the enantiomers are shown in chemical formula representing the compounds. For example, if a compound that includes a chiral center is shown without any indication of stereochemistry, it is presumed to represent all possible stereoisomers of the compound.
  • the term “compound” includes any or all of such forms, whether explicitly stated or not (although at times, “salts" are explicitly stated).
  • the term 'therapeutically effective amount can refer to that amount of a positive allosteric modulator or composition thereof that results in amelioration of symptoms or a prolongation of survival in a subject.
  • a therapeutically relevant effect relieves to some extent one or more symptoms of a medical condition (e.g., obesity or an obesity-related disorder) or returns to normal either partially or completely one or more physiological or biochemical parameters (e.g., an MC4R signaling pathway) associated with or causative of the medical condition.
  • the term “subject” can refer to any animal including, but not limited to, humans and non-human animals (e.g., rodents, arthropods, insects, fish (e.g., zebrafish), non- human primates, ovines, bovines, ruminants, lagomorphs, porcines, caprines, equines, canines, felines, birds, etc.), which is to be the recipient of a particular treatment.
  • non-human animals e.g., rodents, arthropods, insects, fish (e.g., zebrafish), non- human primates, ovines, bovines, ruminants, lagomorphs, porcines, caprines, equines, canines, felines, birds, etc.
  • non-human animals e.g., rodents, arthropods, insects, fish (e.g., zebrafish), non- human primates, ovines, bovines, ruminants, lagomorphs
  • melanocortin receptor can refer to any member of the family of melanocortin receptors including melanocortin- 1 receptor (MC1R), melanocortin-2 receptor (MC2R), melanocortin-3 receptor (MC3R), melanocortin-4 receptor (MC4R), and melanocortin-5 receptor (MC5R).
  • M1R melanocortin- 1 receptor
  • M2R melanocortin-2 receptor
  • M3R melanocortin-3 receptor
  • M4R melanocortin-4 receptor
  • M5R melanocortin-5 receptor
  • allosteric modulator can refer to a compound that does not bind to an orthosteric ligand binding site of a melanocortin receptor, but instead acts elsewhere to modulate melanocortin receptor function or activity. Binding by an allosteric modulator does not trigger a functional activity in the absence of the orthosteric ligand (e.g., a melanocortin receptor agonist).
  • a positive allosteric modulator (PAM) is a compound that amplifies the effect of an orthosteric ligand.
  • modulate can refer to a change in the biological activity of a biologically active molecule (e.g., a melanocortin receptor). Modulation can be an increase or a decrease in activity, a change in binding characteristics, or any other change in the biological, functional, or immunological properties of a biologically active molecule.
  • a biologically active molecule e.g., a melanocortin receptor
  • the term "activity" with reference to melanocortin receptor activity can refer to a cellular, biological, and/or therapeutic activity or function of a melanocortin receptor. Examples of such activities can include, but are not limited to, signal transduction, interacting with binding partners) or cellular components), and modulating cellular responses to stimuli.
  • the term "agonist” can refer to a molecule or compound which, when interacting with a biologically active molecule (e.g., a melanocortin receptor), causes a change (e.g., enhancement) in the biologically active molecule, which modulates the activity of the biologically active molecule.
  • a biologically active molecule e.g., a melanocortin receptor
  • melanocortin receptor agonists are known. See Nargund et ai, J Med Chem. 49: 4035-43 (2006).
  • Examples of MC4R selective agonists include beta-MSH, THIQ, and PF-00446687, as well as the endogenous agonist aMSH.
  • the terms “treating” or “treatment” of a medical condition can include: (1) preventing at least one symptom of the disease, i.e., causing a clinical symptom to not significantly develop in a subject that maybe exposed to or predisposed to the condition but does not yet experience or display symptoms of the condition; (2) inhibiting the disease, i.e., arresting or reducing the development of the condition or its symptoms; or (3) relieving the condition, i.e., causing regression of the condition or its clinical symptoms.
  • Treatment, prevention, and ameliorating obesity or an obesity-related disorder can include, for example, weight loss and/or decreasing insulin resistance associated with the condition.
  • Positive allosteric modulators of melanocortin receptors were identified by following the drug discovery program outlined in Figure 1. Briefly, a real-time cAMP high throughput- screening assay for allosteric modulators of the MC4R was used to identify 2472 positive allosteric modulators, which were then counter-screened at the ⁇ 2-adrenergic receptor to yield 165 MC4R-specific allosteric modulators. Examples showing the results from positive allosteric modulators are shown in Figures 2 and 3. Of the 165 positive allosteric modulators, 76 were validated with 12-point concentration-response curves at the human MC3R and human MC4R.
  • Both MC4R-specific and dual C3R/MC4R positive allosteric modulators were identified. A 600 compound structure-activity relationship was then performed around a subset of 11 of the 76 positive allosteric modulators. Subsets of the 76 positive allosteric modulators were also analyzed using assays for the pharmacological mechanism(s) of action, including: (1) effects of the amplitude and kinetics of the ECtoo response to a-melanocyte-stimulating hormone (aMSH); (2) receptor affinity using europium-labeled Nle4-DPhe7-a-MSH (NDP- MSH); (3) cell surface receptor density using a tagged immunoprecipitable receptor; and (4) receptor densitization using a ⁇ -arrestin recruitment assay.
  • aMSH a-melanocyte-stimulating hormone
  • NDP- MSH europium-labeled Nle4-DPhe7-a-MSH
  • these assays demonstrated that the tested positive allosteric modulators fall into certain mechanistic classes. For example, these assays demonstrated that: (1) certain positive allosteric modulators inhibit ⁇ -arrestin recruitment and, thus, work by blocking desensitization of the MC4R; (2) certain positive allosteric modulators have MC4R-specific activity; and (3) certain positive allosteric modulators depolarize MC4R neurons.
  • the present disclosure provides positive allosteric modulators of melanocortin receptors.
  • a method for treating obesity or an obesity-related disorder e.g., severe obesity caused by melanocortin obesity syndrome.
  • the positive allosteric modulators disclosed herein can increase melanocortin sensitivity to melanocortin receptor agonists (e.g, endogenous aMSH) to selectively modulate G protein-coupled receptor (GPCR) signaling pathways that regulate body weight versus blood pressure.
  • melanocortin receptor agonists e.g, endogenous aMSH
  • GPCR G protein-coupled receptor
  • GPCR signaling pathways may be the result of positive allosteric modulators that increase agonist efficacy at melanocortin receptors (e.g., MC4R) by (1) inhibiting receptor desensitization (e.g., inhibiting coupling to ⁇ -arrestin) and/or (2) activating G protein coupling without blocking receptor desensitization.
  • positive allosteric modulators that increase agonist efficacy at melanocortin receptors (e.g., MC4R) by (1) inhibiting receptor desensitization (e.g., inhibiting coupling to ⁇ -arrestin) and/or (2) activating G protein coupling without blocking receptor desensitization.
  • positive allosteric modulators of a melanocortin receptor are provided, as well as analogs, homologs, and pharmaceutically acceptable salts thereof.
  • Homologs are compounds that form a part of a series, differing from one another by the successive addition of the same chemical moiety, e.g. a -CH2- moiety.
  • ethanol CH3CH2OH
  • n-propanol CH3CH2CH2OH
  • Analog compounds typically have structurally similar nuclei but will differ in a particular chemical moiety.
  • alcohols and esters represent analogs, differing in the presence of a hydrogen and an alkyl group.
  • the compounds having the following structures may be useful in treating a subject having obesity or an obesity-related disorder, such as severe or morbid obesity associated with dysfunctional melanocortin signaling (e.g., melanocortin obesity syndrome due to MC4R-haploinsufficiency).
  • the active compounds identified by inventors are collectively referred to as positive allosteric modulators.
  • the positive allosteric modulators can comprise a positive allosteric modulator for a melanocortin receptor selected from the group consisting of:
  • the positive allosteric modulators can comprise a growth inhibiting compound selected from the group consisting of:
  • the positive allosteric modulators can comprise a ⁇ -arrestin blocker selected from the group consisting of: and analogs, homologs, and pharmaceutically acceptable salts thereof. These compounds are defined herein as the compounds of group III.
  • the positive allosteric modulators of groups I, II, and III are capable of further forming both pharmaceutically acceptable acid addition and/or base salts.
  • AH of these forms are within the scope of the present disclosure, and can be orally administered (e.g., by chronic daily dosing) to a subject to treat a disease mediated by dysfunctional melanocortin receptor signaling.
  • Pharmaceutically acceptable acid addition salts of the present disclosure can include, but are not limited to, salts derived from nontoxic inorganic acids such as hydrochloric, nitric, phospohoric, sulfuric, hydrobromic, hydriodic, hydrofluoric, phosphorous, and the like, as well as the salts derived forth nontoxic organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc.
  • nontoxic inorganic acids such as hydrochloric, nitric, phospohoric, sulfuric, hydrobromic, hydriodic, hydrofluoric, phosphorous, and the like
  • nontoxic organic acids such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids
  • Such salts can thus include sulfate, pyrosulfate, bisulfate, sulfite, bissulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, trifluoracetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinate, suberate, sebacate, fumarate, malcate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, maleate, tartrate, methanesulfonate, and the like.
  • salts of amino acids such as arginate and the like, as well as gluconate, galacturonate, and n-methyl glucos
  • Pharmaceutically acceptable base addition salts can be formed with metals or amides, such as alkali and alkaline earth metals or organic amines.
  • metals used as cations include, but are not limited to, sodium, potassium, magnesium, calcium, and the like.
  • suitable amines include, but are not limited to, N2-N,-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine and procaine.
  • Certain of the compounds of the present invention can exist in unsolvated forms as well as solvated forms, including, but not limited to, hydrated forms.
  • the solvated forms, including hydrated forms can be equivalent to unsolvated forms and are intended to be encompassed within the scope of the present disclosure.
  • Pharmaceutically acceptable carriers for the positive allosteric modulators described herein can be in any suitable form (e.g., solids, liquids, gels, etc.).
  • a solid carrier can be one or more substances, which may also act as diluents, flavoring agents, binders, preservatives, and/or an encapsulating material.
  • positive allosteric modulators (or any analog or homolog thereof) can be administered to a subject in a pharmaceutical composition at a therapeutically effective amount and for a period of time effective to increase melanocortin receptor sensitivity to a melanocortin receptor agonist (as compared to a control).
  • Pharmaceutically acceptable carriers are known in the art, and may include any material(s) that is not biologically or otherwise undesirable, i.e., the material may be incorporated into or added to the positive allosteric modulators) without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the composition.
  • pharmaceutically acceptable when used to refer to a pharmaceutical carrier, it can be implied that the carrier has met the required standards of toxicological and manufacturing testing or that it is included on the Inactive Ingredient Guide prepared by the U.S. Food and Drug administration.
  • the dose, amount, and/or quantity of a positive allosteric modulator, or any analog or homolog thereof, administered to the subject can depend on the specific positive allosteric modulator selected. It will be appreciated that the dosage amounts used will depend on the potency of the specific positive allosteric modulator (or analog or homolog thereof) and the therapeutic regimen employed. Determination of a therapeutically effective amount is within the capability of those skilled in the art. The exact formulation, route of administration, and dosage can be chosen by a medical professional, for example, in view of the subject's disease. It should also be understood that a "therapeutically effective amount” may be interpreted as an amount giving a desired therapeutic effect, whether taken in one dose or in any number of doses, or taken alone or in combination with other compounds. In the case of the present disclosure, a "therapeutically effective amount” may be understood as an amount of one or more positive allosteric modulators described herein required to treat a disease mediated by dysfunctional melanocortin receptor signaling.
  • Candidate agents may be tested in animal models.
  • the animal model is one for the study of obesity or an obesity-related disorder.
  • the study of obesity in animal models is a commonly accepted practice for the determining the effectiveness of compounds in humans. See Carroll et al., Clin Dermatol., 22(4): 345-9 (2004).
  • mice For example, Zucker Fatty, ZDF, G rats, ob/ob & db/db mice are all known to be genetic models for obesity. Results are typically compared between control animals treated with candidate agents and the control littermates that did not receive treatment.
  • Transgenic animal models are also available and are commonly accepted as models for human disease (see, for instance, Greenberg et al., Proc. Natl. Acad. Sci.
  • Candidate agents can be used in these animal models to determine if a candidate agent decreases one or more of the symptoms associated with the obesity, including, for instance, diabetes, hypertension, and fatty liver disease, or combinations thereof.
  • the location(s) where the positive allosteric modulators) and/or composition is/are administered may be determined based on the subject's individual need, such as the particular type of disease.
  • the positive allosteric modulators) and/or composition may be administered to the subject in an orally bioavailable form.
  • routes of administration can be used, such as injection (e.g., intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrasternal routes).
  • the formulations may be conveniently presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Preferably, such methods include the step of bringing the active agent into association with a carrier that constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing the active agent into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product into the desired formulations.
  • the methods of the invention include administering to a subject, preferably a mammal, and more preferably a human, the composition of the invention in an amount effective to produce the desired effect.
  • the formulated compounds can be administered as a single dose or in multiple doses.
  • Useful dosages of the active agents can be determined by comparing their in vitro activity and the in vivo activity in animal models. Methods for extrapolation of effective dosages in mice, and other animals, to humans are known in the art; for example, see U.S. Pat. No. 4,938,949.
  • the agents of the present invention are preferably formulated in pharmaceutical compositions and then, in accordance with the methods of the invention, administered to a subject, such as a human patient, in a variety of forms adapted to the chosen route of administration.
  • the formulations include, but are not limited to, those suitable for oral, rectal, vaginal, topical, nasal, ophthalmic, or parental (including subcutaneous, intramuscular, intraperitoneal, and intravenous) administration.
  • Formulations of the present invention suitable for oral administration may be presented as discrete units such as tablets, troches, capsules, lozenges, wafers, or cachets, each containing a predetermined amount of the active agent as a powder or granules, as liposomes containing the active compound, or as a solution or suspension in an aqueous liquor or non-aqueous liquid such as a syrup, an elixir, an emulsion, or a draught.
  • Such compositions and preparations typically contain at least about 0.1 wt-% of the active agent.
  • the amount of the compound of the invention i.e., active agent
  • the amount of the compound of the invention is such that the dosage level will be effective to produce the desired result in the subject.
  • the tablets, troches, pills, capsules, and the like may also contain one or more of the following: a binder such as gum tragacanth, acacia, com starch or gelatin; an excipient such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid, and the like; a lubricant such as magnesium stearate; a sweetening agent such as sucrose, f uctose, lactose, or aspartame; and a natural or artificial flavoring agent.
  • a binder such as gum tragacanth, acacia, com starch or gelatin
  • an excipient such as dicalcium phosphate
  • a disintegrating agent such as corn starch, potato starch, alginic acid, and the like
  • a lubricant such as magnesium stearate
  • a sweetening agent such as sucrose, f uctose, lactose, or as
  • Various other materials may be present as coatings or to otherwise modify the physical form of the solid unit dosage form.
  • tablets, pills, or capsules may be coated with gelatin, wax, shellac, sugar, and the like.
  • a syrup or elixir may contain one or more of a sweetening agent, a preservative such as methyl- or propylparaben, an agent to retard crystallization of the sugar, an agent to increase the solubility of any other ingredient, such as a polyhydric alcohol, for example glycerol or sorbitol, a dye, and flavoring agent.
  • the material used in preparing any unit dosage form is substantially nontoxic in the amounts employed.
  • the active agent may be incorporated into sustained-release preparations and devices.
  • a method for treating obesity or an obesity-related disorder in a subject includes administering a therapeutically effective amount of a pharmaceutical composition including a positive allosteric modulator of melanocortin receptors to the subject.
  • the positive allosteric modulator can be any of the melanocortin receptor affecting compounds described herein.
  • the at least one positive allosteric modulator can be administered in an amount effective to increase melanocortin receptor sensitivity to a melanocortin agonist ⁇ e.g., endogenous aMSH) as compared to a control.
  • the at least one positive allosteric modulator can include any one or combination of the compounds of groups I, II, or III.
  • medical conditions treatable by administering a therapeutically effective amount of at least one positive allosteric modulator can include obesity and obesity- related disorders mediated by dysfunctional melanocortin receptor signaling, such as dysfunctional MC4R signaling.
  • obesity treatable by administration of pharmaceutical compositions including a positive allosteric modulator of melanocortin receptors includes severe or morbid obesity caused by MC4R-haploinsufficiency.
  • obesity or an obesity-related disorder treatable by the present disclosure can be caused by inadequate production of one or more melanocortin receptor agonists.
  • a disease mediated by dysfunctional melanocortin receptor signaling can refer to a disease that involves dysfunction of activity of a melanocortin receptor, a signal transduction pathway associated with a melanocortin receptor, or an activity or signal transduction pathway that is mediated by a melanocortin receptor.
  • a disease mediated by dysfunctional melanocortin receptor signaling can include a disease where a melanocortin receptor activity or signal transduction pathway can be modulated for treatment of the disease.
  • compositions and methods that modulate a melanocortin receptor activity and/or melanocortin receptor signal transduction pathway(s) to provide a therapeutic benefit or therapeutic activity for treatment of a disease, such as severe or morbid obesity caused by melanocortin obesity syndrome.
  • the melancortin-4 receptor acts as a control for energy storage.
  • treating severe or morbid obesity caused by haploinsufficiency of the MC4R may be compared to other syndromes of hormone insufficiency, where the goal is to restore functioning of the signaling pathway to normal levels to reverse the disease.
  • administration of positive allosteric modulators may increase MC4R receptor sensitivity to ⁇ MSH (as compared to a control) and thereby increase the level of MC4R signaling (e.g., from the roughly 50% level seen in MC4R- haploinsufficiency) to normal or wild-type levels.
  • a positive allosteric modulator may inhibit or mitigate MC4R desensitization by inhibiting ⁇ -arrestin coupling.
  • a positive allosteric modulator may additionally or alternatively activate G protein coupling without inhibiting or blocking MC4R desensitization.
  • the positive allosteric modulators of the present disclosure can increase MC4R signaling without unwanted pressor side effects, thereby restoring function of one or more GPCR signaling pathways that regulate body weight versus blood pressure.
  • the positive allosteric modulators of melanocortin receptor activity described herein are used to treat obesity, including severe and morbid obesity.
  • obesity can refer to a medical condition in which excess body fat has accumulated to the extent that it may have an adverse effect (both physical and mental) on health, leading to reduced life expectancy and/or increased health problems.
  • the obesity can be the result of anything that leads to the accumulation of excess body fat, such as dietary obesity.
  • Body mass index (BMI), a measurement which compares weight and height (calculated from an subject's weight divided by the square of the height), defines subjects as overweight (pre-obese) when their BMI is between 25 kg/m2 and 30 kg/m2, and obese when it is greater than 30 kg/m2.
  • Obesity can also be defined as a condition whereby a subject with at least one co-morbidity has a BMI greater than or equal to 27 kg/m2.
  • An "obese subject” can be an otherwise healthy subject with a BM) greater than or equal to 30 kg/m2, or a subject with at least one co-morbidity with a BMI greater than or equal to 27 kg/m2.
  • obesity can be defined in terms of body fat percentage, which can be quantified by a variety of means recognized in the art, such as body average density measurement, bioelectric impedance, skinfold method, height and circumference method, as well as BMI.
  • severe obesity and “morbid obesity” can refer to subjects who are about 50% to 100% - or 100 pounds above - their ideal body weight. Alternatively, a BMI value greater than 39 may be indicative of severe or morbid obesity.
  • the positive allosteric modulators of melanocortin receptor activity described herein are used to treat an obesity-related disorder.
  • obesity-related disorder can refer to any disorder associated with obesity, such as atherosclerosis, insulin resistance, type 2 diabetes, hypertension, hyperlipidemia, hypertriglyceridemia, cardiovascular disease, microangiopathy in obese individuals with type 2 diabetes, ocular lesions associated with microangiopathy in obese individuals with type 2 diabetes, renal lesions associated with microangiopathy in obese individuals with type 2 diabetes, metabolic syndrome, syndrome X, a fatty liver, fatty liver disease, polycystic ovarian syndrome, hemochromatosis and acanthosis nigricans.
  • the positive allosteric modulator compounds of groups I, II and III described herein can also be used to affect melanocortin receptor activity.
  • a method of activating a melanocortin receptor by positive allosteric modulation includes the step of contacting a melanocortin receptor with a compound of group I or group II.
  • a method of blocking coupling of a melanocortin receptor to ⁇ -arrestin is provided that includes the step of contacting a melanocortin receptor with a compound of group III.
  • the ability of the compounds of groups I and III to modulate melanocortin receptor activity were identified by following the drug discovery program shown in Figure 1.
  • the compounds of group II, on the other hand, were identified on the basis of in vivo activity using the zebrafish assay described herein.
  • Use of the compounds of groups I, II and III to affect melanocortin receptor activity includes the step of contacting a melanocortin receptor with a compound of group I, group II, or group III.
  • the melanocortin receptor can be a melanocortin- 3 receptor (MC3R) or a melanocortin-4 receptor (MC4R).
  • M3R melanocortin- 3 receptor
  • M4R melanocortin-4 receptor
  • Contacting refers to playing the positive allosteric modifying compound in an environment at a concentration and proximity such that it can be expected to contact the melanocortin receptor and thereby allosterically modify its activity.
  • the melanocortin receptor can be present on a cell, such as a cell of the central nervous system.
  • the melanocortin receptor can also be contacted by the positive allosteric modulator either in vitro, ex vivo, or in vivo.
  • the melanocortin receptor When the melanocortin receptor is contacted in vivo, it may be present in a subject or patient, such as a human subject. It may be desirable to contact melanocortin receptors with compounds of the present invention for research purposes, to provide a therapeutic effect, or for a variety of other reasons.
  • a method for characterizing a compound that modulates melanocortin receptor activity.
  • the method can include the steps of: (a) providing a population of cells expressing at least one melanocortin receptor, the cells being disposed in a vessel containing a luminescent substrate; (b) contacting the cell population with a test compound; (c) contacting the cell population with a melanocortin receptor agonist; and (d) determining a cAMP response profile for the test compound; wherein the cAMP response profile is indicative of whether the test compound is inactive, orthosteric, allosteric or inhibitory.
  • the method can include a high-throughput 384 plate kinetic assay for MC4R function as described in Pantel et al, Eur J Pharmacol 660:139-147 (2011).
  • HEK293 cells stably expressing hMC4R and a fluorescent cAMP reporter e.g., the PROMEGA PGLO cAMP report, Promega Corporation, Madison, WI
  • a fluorescent cAMP reporter e.g., the PROMEGA PGLO cAMP report, Promega Corporation, Madison, WI
  • Each cell-containing well which can be preloaded with the luminescent substrate, can be injected first with a test compound.
  • a melanocortin receptor agonist e.g., aMSH
  • a cAMP response profile can be determined for the tested compound.
  • the cAMP response profile can allow identification and classification of tested compounds as inactive, orthosteric, allosteric or inhibitory.
  • the assay can be used to identify a positive allosteric modulator, such as those disclosed herein.
  • One aspect of the invention provides a method of blocking coupling of a melanocortin receptor to ⁇ -arrestin.
  • ⁇ -arrestin can be assayed using the commercially available PathHunterTM ⁇ -arrestin recruitment assay.
  • thawing and plating frozen PathHunterTM eXpress cells from freezer vials is carried out.
  • the optimized cell culture (OCC) medium is prewarmed in a 37°C water bath.
  • Cell vial(s) are removed from -80°C or liquid N2 vapor plate storage and place immediately on dry ice prior to thawing, without exposing the vials to room temperature.
  • Hie cell vial(s) are then briefly (10 seconds to 1 min) placed in a 37° C water bath until only small ice crystals remain and the cell pellet(s) is almost completely thawed.
  • 0.5 mL of prewarmed OCC medium is added to the cell vial.
  • test compound ⁇ i.e., a positive allosteric modulator of group I, II, or III
  • concentration of the compound should be 22x of the final screening concentration (220 ⁇ ).
  • the PathHunterTM eXpress cells (previously plated on day 1) are then removed from the incubator. Transfer 5 ⁇ L of the compounds to each appropriate well, and incubate for 5 minutes at 37°C.
  • the agonist compound is then prepared and added. First, prepare a 22x EC100 concentration (2.2 ⁇ ) of the agonist. Next, 5 ⁇ L of agonist compound is added to each well, and incubated for 90 minutes at 37°C.
  • a working stock of PathHunterTM Detection Reagents can be prepared by mixing 19 parts Cell Assay Buffer, 5 parts Substrate Reagent 1 and 1 part Substrate Reagent 2. Add 55 ⁇ L of prepared detection reagent per well and incubate for 60 minutes at room temperature (23° C). Results are obtained by reading the chemiluminescent signal.
  • Compounds of the invention may be synthesized by synthetic routes that include processes similar to those well known in the chemical arts.
  • the starting materials are generally available from commercial sources such as Aldrich Chemicals (Milwaukee, Wisconsin, USA) or are readily prepared using methods well known to those skilled in the art (e.g., prepared by methods generally described in Louis F. Fieser and Mary Fieser, Reagents for Organic Synthesis, v. 1-19, Wiley, New York, (1967-1999 ed.); Alan R. Katritsky, Otto Meth-Cohn, Charles W. Rees, Comprehensive Organic Functional Group Transformations, v 1-6, Pergamon Press, Oxford, England, (1995); Barry M.
  • Example 1 Zebrafish Assay for Melanocortin 4 Receptor Activation
  • the endogenous MC4R antagonist, AgRP must first be inhibited by injection of specific antisense morpholino oligonucleotide.
  • Antisense morpholino oligonucleotide (MO) against the ATG translation initiation site of zebrafish agrp was designed and synthesized from GeneTools. Morpholino oligonucleotide was dissolved in nuclease- free water and stored in -20° C as 1 mM stock.
  • 0.1 mM working dilution was made using nuclease-free water with 20% Phenol Red (Sigma, 0.5% in DPBS, sterile filtered, endotoxin tested). Before the injection, MO was denatured at 65°C for 5min and quickly spun to avoid the formation of aggregates. S ⁇ L was loaded into a capillary, needle on a microinjection machine. WT or MC4R null zebrafish embryos at one or two cell stages were injected with 2nL of 0.1 mM agrp morpholino solution (-2.0 ng per egg).
  • Embryos were rinsed 5-6 times in fresh egg water and 45 live embryos were transferred into single well on a 12- well cell culture plate in 4 ml fresh egg water.
  • 10 mM stock compound solutions were prepared in 100% DMSO.
  • Peptides were dissolved in distilled water and 100 ⁇ stock solutions were made in water with 10% DMSO.
  • a 4 ⁇ L compound solution or 40 ⁇ L peptide solution was added and mixed into each well to make 10 ⁇ L final concentration with 0.1% DMSO.
  • Wells with 0.1% DMSO or 10 ⁇ ⁇ -MSH were included as vehicle or positive controls, respectively. Compound/peptide solutions were changed daily.
  • Example 2 Treatment of a Mouse with a Melanocortin Receptor Activator
  • mice were placed on high fat diet for 5 days.
  • Osmotic pumps were filled with vehicle (25% DMSO, 25% saline, 50% EtOH) or VU0055768 (25% compound in DMSO, 25% saline, 50% EtOH) as to deliver 2.5 mg/kg/day, and were then inserted subcutaneously (6 vehicle, 5 compound) into the mice.
  • the mice were fed ad-libidum with high fat diet.
  • Mouse and food weight was measured daily.
  • Statistical analysis of the results was t-test. The results are shown in Figure 6, which shows that mice fed VU 0055768 showed significantly reduced weight gain.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention concerne des modulateurs allostériques positifs des récepteurs de la mélanocortine, en particulier des potentialisateurs allostériques des récepteurs MC3R et MC4R. Elle concerne également des compositions pharmaceutiques contenant les modulateurs allostériques positifs et des procédés de traitement de l'obésité ou un trouble lié à l'obésité tel que le diabète de type 2, comprenant l'administration d'une quantité efficace du modulateur allostérique positif.
PCT/US2013/029353 2012-03-06 2013-03-06 Modulateurs allostériques positifs pour récepteurs de mélanocortine WO2013134376A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/383,715 US9744171B2 (en) 2012-03-06 2013-03-06 Positive allosteric modulators for melanocortin receptors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261607329P 2012-03-06 2012-03-06
US61/607,329 2012-03-06

Publications (1)

Publication Number Publication Date
WO2013134376A1 true WO2013134376A1 (fr) 2013-09-12

Family

ID=49117288

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/029353 WO2013134376A1 (fr) 2012-03-06 2013-03-06 Modulateurs allostériques positifs pour récepteurs de mélanocortine

Country Status (2)

Country Link
US (1) US9744171B2 (fr)
WO (1) WO2013134376A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017027845A1 (fr) * 2015-08-12 2017-02-16 Memorial Sloan-Kettering Cancer Center Dérivés phénylsulfonamido-benzofurane et leur utilisation dans le traitement de maladies prolifératives
EP2919770A4 (fr) * 2012-11-14 2017-03-08 The Board of Regents of The University of Texas System Inhibition de l'hétérodimérisation de hif-2 avec hif1 (arnt)
KR101909258B1 (ko) 2018-05-16 2018-10-17 전남대학교산학협력단 피부 노화 예방 또는 치료용 약학 조성물, 건강기능식품 및 화장료 조성물
CN110540541A (zh) * 2019-09-11 2019-12-06 广西师范大学 6H-吲哚并[2,3-b]喹喔啉类化合物及其制备方法和应用
WO2022106588A1 (fr) * 2020-11-20 2022-05-27 F. Hoffmann-La Roche Ag Dérivés de 2-phénylbenzotriazol-5-amine pour le traitement et la prophylaxie d'une infection par le virus de l'hépatite b (vhb)
US11932628B2 (en) 2021-01-04 2024-03-19 Regents Of The University Of Minnesota Selective small molecule peptidomimetic melanocortin ligands

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107501283B (zh) 2017-09-13 2020-06-02 北京师范大学 取代芳甲杂基取代苯胺基缩乙二醇醚环代喹唑啉的制备及肿瘤治疗药物应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070149562A1 (en) * 2004-07-29 2007-06-28 Sanofi-Aventis Oxopiperidine derivatives, preparation and therapeutic use thereof
US20090312345A1 (en) * 2005-06-03 2009-12-17 Amicus Therapeutics, Inc. Pharmacological chaperones for treating obesity
US20100087468A1 (en) * 2004-08-13 2010-04-08 Metabolex, Inc. Modulators of ppar and methods of their preparation
US20100311648A1 (en) * 2009-06-08 2010-12-09 Astrazeneca Ab Melanocortin receptor-specific peptides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070149562A1 (en) * 2004-07-29 2007-06-28 Sanofi-Aventis Oxopiperidine derivatives, preparation and therapeutic use thereof
US20100087468A1 (en) * 2004-08-13 2010-04-08 Metabolex, Inc. Modulators of ppar and methods of their preparation
US20090312345A1 (en) * 2005-06-03 2009-12-17 Amicus Therapeutics, Inc. Pharmacological chaperones for treating obesity
US20100311648A1 (en) * 2009-06-08 2010-12-09 Astrazeneca Ab Melanocortin receptor-specific peptides

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE PUBCHEM 8 July 2005 (2005-07-08), accession no. ID 741095 *
ELLACOTT ET AL.: "The role of the central melanocortin system in the regulation of food intake and energy homeostasis: lessons from mouse models", PHIL. TRANS. R. SOC. B, vol. 361, 2006, pages 1265 - 1274, Retrieved from the Internet <URL:rstb.royalsocietypublishing.org> *
PANTEL ET AL.: "Development of a high throughput screen for allosteric modulators of melanocortin-4 receptor signaling using a real time cAMP assay", EUR J PHARMACOL., vol. 660, no. 1, 11 June 2011 (2011-06-11), pages 139 - 147 (1-20), Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pmc> *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2919770A4 (fr) * 2012-11-14 2017-03-08 The Board of Regents of The University of Texas System Inhibition de l'hétérodimérisation de hif-2 avec hif1 (arnt)
US9757379B2 (en) 2012-11-14 2017-09-12 The Board Of Regents Of The University Of Texas System Inhibition of HIF-2α heterodimerization with HIF1β (ARNT)
WO2017027845A1 (fr) * 2015-08-12 2017-02-16 Memorial Sloan-Kettering Cancer Center Dérivés phénylsulfonamido-benzofurane et leur utilisation dans le traitement de maladies prolifératives
US10975051B2 (en) 2015-08-12 2021-04-13 Memorial Sloan Kettering Cancer Center Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases
US11098021B2 (en) 2015-08-12 2021-08-24 Memorial Sloan-Kettering Cancer Center Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases
KR101909258B1 (ko) 2018-05-16 2018-10-17 전남대학교산학협력단 피부 노화 예방 또는 치료용 약학 조성물, 건강기능식품 및 화장료 조성물
CN110540541A (zh) * 2019-09-11 2019-12-06 广西师范大学 6H-吲哚并[2,3-b]喹喔啉类化合物及其制备方法和应用
WO2022106588A1 (fr) * 2020-11-20 2022-05-27 F. Hoffmann-La Roche Ag Dérivés de 2-phénylbenzotriazol-5-amine pour le traitement et la prophylaxie d'une infection par le virus de l'hépatite b (vhb)
US11932628B2 (en) 2021-01-04 2024-03-19 Regents Of The University Of Minnesota Selective small molecule peptidomimetic melanocortin ligands

Also Published As

Publication number Publication date
US20150018371A1 (en) 2015-01-15
US9744171B2 (en) 2017-08-29

Similar Documents

Publication Publication Date Title
US9744171B2 (en) Positive allosteric modulators for melanocortin receptors
AU2021204261B2 (en) 5ht agonists for treating disorders
Olivier et al. Serotonin receptors and animal models of aggressive behavior
JP2010530736A (ja) タプシガルジンにより誘導される細胞死の阻害剤
JP2021534248A (ja) ３−アリールオキシル−３−５員ヘテロアリール−プロピルアミン化合物およびその使用
JP7283669B2 (ja) ３－アリールオキシ－３－アリール－プロピルアミン化合物およびその用途
MX2008012492A (es) Compuestos de diariltiohidantoina.
WO2002028832A2 (fr) Compositions de diindolylmethane et de diindolylmethane c-substitue et procedes de traitement de cancers multiples
EP3670509B1 (fr) Inhibiteurs de la leucémie inv (16)
CN108366997A (zh) 治疗痛觉过敏的方法
WO2013033520A1 (fr) Procédé de régulation de la pigmentation de la peau
CN107625762A (zh) 萘环类药物的新用途
Boccella et al. 2-Pentadecyl-2-oxazoline ameliorates memory impairment and depression-like behaviour in neuropathic mice: possible role of adrenergic alpha2-and H3 histamine autoreceptors
Aizawa et al. Efficacy of the combination of KPR-5714, a novel transient receptor potential melastatin 8 (TRPM8) antagonist, and β3-adrenoceptor agonist or anticholinergic agent on bladder dysfunction in rats with bladder overactivity
US9945845B2 (en) Methods of screening using amphibians
KR20140032916A (ko) 에틸（２―메틸―３―｛（Ｅ）―［（나프타［２，１―ｂ］퓨란―２―일카보닐）하이드라조노］메틸｝―1Ｈ―인돌―1―일）아세테이트, 이의 유사체를 유효성분으로 포함하는 암 예방 및 치료용 조성물
WO2008157407A2 (fr) Compositions et procédés pour traiter la leucémie
US20120115778A1 (en) Methods of Suppressing Appetite by the Administration of Antagonists of the Serotonin HTR1a or HTR2b Receptors or Inhibitors of TPH2
Lima et al. Antispasmodic and myorelaxant effects of the flavoring agent methyl cinnamate in gut: Potential inhibition of tyrosine kinase
US9040713B2 (en) Methods of managing blood sugar levels and compositions related thereto
BR112019016775A2 (pt) Compostos moduladores de receptor delta-opioide contendo aza-heterocíclico com 7 membros, métodos de uso e produção dos mesmos
WO2014059305A1 (fr) Composés permettant de traiter un trouble médié par la rac-gtpase
US8901155B2 (en) Method for treating a TRPV1-mediated disease
US10688063B2 (en) Treating and/or preventing insulin-resistance related weight gain
CN113677334B (zh) 瞬时受体电位melastatin 8(trpm8)拮抗剂和相关方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13758665

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 14383715

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 13758665

Country of ref document: EP

Kind code of ref document: A1